DIRS.INFO The most relevant business & tech news

☆ How to access the new weight loss drugs
▼ + stars: | 2024-02-15 | by ( Andrea Kane | ) edition.cnn.com time to read: +7 min

(CNN) — By now, it is pretty clear that the new weight loss and diabetes medications have achieved blockbuster status. Unlike previous weight loss medications, they are pretty effective at helping people lose weight and keep it off — between around 15% to 20% of body weight — with relatively few side effects (although some people can’t tolerate them, and a fraction of patients experience more severe side effects). Zepbound, the newly approved weight loss drug from Eli Lilly, may be easier to find. “Otherwise, some physicians are prescribing older, generic weight loss medications that can be helpful for some patients.”These drugs are not right for everyoneFor many people, the cultural pressure to look a certain way is high. And join us next week on the Chasing Life podcast when we talk to WeightWatchers CEO Sima Sistani about whether these new weight loss drugs really signal the end of diet culture.

Persons: Sanjay Gupta ”, Eli Lilly, Goldman Sachs, Meg Tirrell John Nowak “, Meg Tirrell, Sanjay Gupta, ” Tirrell, “, ” Eli Lilly, Tirrell, ”, Sima Sistani Organizations: CNN, —, Trilliant Health, Novo Nordisk, US Food and Drug Administration, “, Nordisk, ”

☆ In this fast-paced bull market, we're increasing our Club price targets on 4 stocks
▼ + stars: | 2024-02-15 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Following last week's $120-per-share price target hike to $750 on strong earnings, we're raising our PT again Thursday to $850. Even at our new $850 price target, Lilly shares still represent a lower PEG than we've seen historically but that provides some margin of safety. Costco price target hike to $770 from $680 Costco also trades at a premium valuation, but we think it's warranted due to the company's reliability and consistency. Salesforce price target hike to $320 from $275 Salesforce is a Club name we recently highlighted in our 10 undervalued stocks commentary . Palo Alto Networks price target change pending Lastly, we are aware that our price target on Palo Alto Networks requires an update as well.

Persons: It's, Eli Lilly, Lilly, Salesforce, –, There's, Jim Cramer's, Jim Cramer, Jim, Robert Nickelsberg Organizations: Wall, PT, Novo Nordisk, Costco, Microsoft, Broadcom, UBS, VMware, JPMorgan, Palo Alto, Palo Alto Networks, Palo, CNBC, Getty Locations: GLP, AVGO, Palo Alto, Palo, New York City

☆ Ozempic, Mounjaro and hundreds of other drugs become even more expensive in 2024
▼ + stars: | 2024-02-15 | by ( Tami Luhby | ) edition.cnn.com time to read: +8 min

Novo Nordisk boosted the list price of Ozempic by 3.5% to $969 for a four-week supply. Eli Lilly last month raised the list price of Mounjaro by 4.5% to $1,069 for a four-week supply. However, they may have to pay the list price if they are uninsured or have not yet hit their annual deductible. Former President Donald Trump, who is running for election again, also unveiled several proposals and issued executive orders aimed at lowering drug costs during his administration. Another factor is the recent policies that penalize pharmaceutical manufacturers for raising list prices faster than inflation.

Persons: Drugmakers, Eli Lilly, Eli Lilly’s Zepbound, Ozempic, Eli Lily, Marlene Foss, Foss, “, ”, Mark Rapp, Rapp, ’ ”, Mark Rapp's, grandkids, ” Rapp, Joe Biden’s, Donald Trump, We’ve, Antonio Ciaccia, we’ve Organizations: New, New York CNN, Ozempic, Novo Nordisk, CNN, Food and Drug Administration, Nordisk’s, Mounjaro, Medicare, ”, White House Locations: New York, Portugal, Doylestown , Pennsylvania, Italy, Mansfield , Ohio, Ohio, Idaho

☆ What Ozempic Taught Me About Shame — and Willpower
▼ + stars: | 2024-02-15 | by ( Albert Fox Cahn | ) www.businessinsider.com time to read: +16 min

It will mean fundamentally reevaluating our conception of free will and human agency — and reckoning with our tortured relationship with shame. Many health plans have refused to cover GLP-1s for weight loss , citing limited approval from the Food and Drug Administration. I don't know when I first became overweight, but I remember the moment I was taught to be ashamed of it. They can stop the vicious feedback loop where our food choices and weight drive the shame that drives our food choices and weight. But no matter how heavy that burden was, one thing made it easier to bear: I wasn't weighed down by my shame.

Persons: I'd, They're, —, dieters, I've, Wayne LaPierre, David Vades Joseph, Mounjaro, …, you'd, would've, Kit Kat, they've, untangling, Stephen Spielberg's Organizations: National Rifle Association, NRA, Food and Drug Administration, New York City Marathon, Harvard Law School, GLP, BI Locations: York, Greenwich Village, darting, GLP

☆ Here's why we would be considering buying more Eli Lilly shares if they were down Tuesday
▼ + stars: | 2024-02-13 | by ( Morgan Chittum | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. If Lilly shares weren't climbing higher in Tuesday's down market, we would consider buying more, given the solid fundamentals and serious growth prospects. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, we're, Jefferies, Palo, Eli Lilly's, Eli Lilly, We're, —, Lilly, Jim Cramer's, Jim Organizations: CNBC, Dow, Nasdaq, Wall, Palo Alto Networks, Jefferies, Palo, Pfizer, Novo Nordisk Locations: Palo Alto

☆ Why Tuesday's pullback is a healthy break in the rally and how we are playing it
▼ + stars: | 2024-02-13 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. A healthy break: Stocks are down after the consumer price index came in slightly hot, leading to a delay in interest rate cut expectations. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, we'll, it's, Eli Lilly, Cramer, Bob Iger's, Stanley Black, Decker, Martin, Jim Cramer's, Jim, NVIDIA Jensen Huang, Michael M Organizations: CNBC, Nvidia, U.S, Treasury, Utilities, Disney, MGM Resorts, Martin Marietta Materials, CME Group, Barrick Gold, Jim Cramer's Charitable, NVIDIA, New York Times, Santiago, Getty Locations: We're, Philadelphia, Robinhood, New York City

☆ Cramer says weight loss drugs could bring down stocks in the food and beverage sector
▼ + stars: | 2024-02-12 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

CNBC's Jim Cramer on Monday told investors to be wary of some food and beverage stocks as investors are captivated by companies that make newly popular GLP-1s, weight loss and diabetes drugs such as Mounjaro and Zepbound. "Stay away from these food and beverage stocks because there will be a day, that day will come, when one of them finally admits they've been hurt by the GLP-1s, and that will take down every stock in the group," he said. But there are other variables that could contribute to weaker sales for food and beverage companies, he said. Cramer conceded that it's hard to predict just how much these drugs will affect food stocks going forward, but said they will definitely change the market. "However, you're fooling yourself if you think these drugs didn't play some sort of role."

Persons: CNBC's Jim Cramer, they've, Cramer Organizations: PepsiCo

☆ Palo Alto, Eli Lilly and Eaton are up big. Here are entry prices for new investors
▼ + stars: | 2024-02-11 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

Palo Alto Networks , Eli Lilly , and Eaton rallied hard over the past 12 months — up 127%, 117% and 66%, respectively. This $315 level is also close to the 50-day simple moving average (red line). Eli Lilly Two potential entry points: $617 (the 50-day simple moving average) and $541 (the 200-day simple moving average) The 50-day simple moving average is $617, a roughly 16.5% pullback from current levels, while the 200-day simple moving average is $541, a 27% decline. Instead, keep a close eye on that 50-day moving average, looking for that gap between the moving average and the stock price to narrow. As we can see, $242 represents the current 50-day moving average, with $240 representing a level of resistance shares recently surpassed.

Persons: Eli Lilly, Eaton, it's, pullbacks, PANW, Mounjaro, they've, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: Palo Alto Networks, Big Tech, Palo Alto, Jim Cramer's Charitable, CNBC, Bloomberg, Getty Locations: Provo , Utah

☆ Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
▼ + stars: | 2024-02-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Victoria Klesty | ReutersThe insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly , have said supply woes likely won't go away anytime soon, as the popularity of those medicines continues to soar. Some Wall Street analysts project that the weight loss drug market could be worth $100 billion by the end of the decade. But both Novo Nordisk and Eli Lilly gave updates on positive supply developments to investors over the last week. Other forms of weight loss drugs could helpAlternative forms of weight loss drugs could also help alleviate supply constraints in the future.

Persons: Victoria Klesty, Eli Lilly, Cantor Fitzgerald, Louise Chen, Nordisk's Wegovy, Eli Lilly's Zepbound, Goldman Sachs, Jeff Friedman, Novo, Mike Segar, Eli, Catalent, Yves Herman Yves Herman, TD Cowen, Michael Nedelcovych, Anat Ashkenazi, Cantor Fitzgerald's Chen, Morgan Stanley, Eli Lilly's, George Frey Organizations: Novo Nordisk, CNBC, Nordisk's, University of Florida, Pfizer, AstraZeneca, Roche, Food, Nordisk, Company, FDA, Novo Holdings, Wegovy, REUTERS, Reuters, U.S Locations: Oslo, Norway, Novo, U.S, Branchburg , New Jersey, Brussels, Belgium, Catalent, Concord , North Carolina, North, Germany, Indiana, Denmark, France

☆ These are the most overbought stocks due for a pullback during S&P's run to 5,000
▼ + stars: | 2024-02-09 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Stocks have raced ahead this year, with the S & P 500 trading above the historic 5,000 level. Stocks that have a 14-day RSI greater than 70 are considered to be overbought, meaning they could be at risk of a pullback. Several firms, from Deutsche Bank to Bank of America, walked away from the company's earnings release even more encouraged about its future. On average, analysts have a $111.38 price target on Disney, indicating less than 1% upside from the entertainment giant's last close. Other overbought companies in the S & P 500 are Boston Scientific and Ralph Lauren , which saw shares reach a 9-year high on the company's earnings beat this week.

Persons: Eli Lilly, Morgan Stanley, Eli Lilly's, Wells, Mohit Bansal, LLY, Walt Disney, Berkshire Hathaway, Nelson Peltz, Ralph Lauren Organizations: Nvidia, Dow Jones, CNBC, Stock, Deutsche Bank to Bank of America, Berkshire, Disney, Epic Games, ESPN, Boston Scientific Locations: Zepbound, Fortnite

☆ Sitting on gains in Eli Lilly, Nvidia? Ask these questions before your next move
▼ + stars: | 2024-02-09 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +10 min

Eli Lilly has jumped almost 27%, building on its 59% gain in 2023. The long-term outlooks for Nvidia and Eli Lilly — both longtime Club holdings — brightened in recent weeks, leading to additional gains for the stocks. This leaves Club members who own Nvidia, Eli Lilly, or both, wondering how to proceed with their investments. Right now, we feel good about the timing of our most recent sales in Nvidia and Eli Lilly. Eli Lilly's stock is currently up about 24% from our Sept. 12 sale level, based on Thursday's close.

Persons: Eli Lily, Eli Lilly, Eli Lilly —, Eli Lilly's, Zepbound, Lilly's, Jim Cramer, Jim, There's, they're, Colette Kress, Goldman Sachs, FactSet, Lilly, Novo, Nordisk's Wegovy, tirzepatide, Jim Cramer's Organizations: Nvidia, Club, Apple, Microsoft, Web Services, Nordisk's, CNBC, Reuters Locations: Wall

☆ Ro, the $7 billion healthcare startup, has a high-stakes strategy to take off-brand Ozempic mainstream
▼ + stars: | 2024-02-07 | by ( ) www.businessinsider.com time to read: +11 min

The $7 billion healthcare startup Ro, which has been prescribing brand-name weight-loss shots since January 2023, now offers compounded semaglutide to patients enrolled in its weight-management program. Nonetheless, Ro is the first prominent healthcare company to effectively endorse compounded semaglutide by prescribing it. A poor-quality compounded drug might simply be a dud and a waste of money. But while compounding pharmacies are subject to FDA and state regulations, states are the main regulators, and their oversight is patchy. Michael Siluk/UCG/Universal Images Group via Getty ImagesIt's hard to know if any given vial of compounded semaglutide is safe.

Persons: Wegovy's, Ro, drugmakers, Eli Lilly's, Eli Lilly's Mounjaro, Scott Gottlieb, Michael Siluk, That's, they've, Ozempic, Eli Lilly, Eric Kastango, they're, Kastango, aren't, Al Carter, Sarah Jones Simmer, Spencer Nadolsky, WeightWatchers, Tim Church, Wondr, it's, hasn't Organizations: Business, Novo Nordisk's Wegovy, US Food and Drug Administration, FDA, Novo Nordisk's Ozempic, Getty, Novo Nordisk, USP, National Association of, Pharmacy, Health Locations: Novo, Massachusetts, Austria, New York City

☆ Wednesday analyst calls: JPMorgan downgrades New York Community Bancorp, Eli Lilly gets big boost
▼ + stars: | 2024-02-07 | by ( Pia Singh | ) www.cnbc.com time to read: +8 min

Troubled regional bank New York Community Bank faced a downgrade from JPMorgan, which said NYCB is facing a multitude of challenges. The firm upped its price target for the drug maker to $850, all the way from $200. Wells Fargo : Analyst Zachary Fadem kept his overweight rating and raised his target price by $200 to $2,800, implying 12.5% upside for shares. "After speaking to management, we confirmed these two executives had indeed left the company, wrote JPMorgan analyst Steven Alexopoulos. NXP's stock price is down 2.9% for the year, but still higher than 15% over the past 12 months.

Persons: Eli Lilly, Eric Gonzalez, Gonzalez, Wells, Zachary Fadem, Sara Senatore, Chipotle, — Pia Singh, JPMorgan downgrades, Steven Alexopoulos, Alexopoulos, John Melloy, Vivek Arya, Arya, Robyn Karnauskas, Karnauskas, Zepbound Organizations: CNBC, New York Community Bank, JPMorgan, Pharma, Truist Securities, Semiconductors, Bank of America, KeyBanc, Barclays, New York Community Bank JPMorgan, New, Community Bank, Financial Times, Bloomberg News, New York Community Bancorp, Battery Management Systems, Food and Drug Administration Locations: Wells Fargo, Tuesday's

☆ Three stocks stocks that could replace Tesla in the Magnificent 7
▼ + stars: | 2024-02-07 | by ( Yun Li | ) www.cnbc.com time to read: +2 min

Now some on Wall Street believe Tesla no longer deserves to be among the coveted " Magnificent 7 ," and are suggesting alternatives that could replace Elon Musk's company. "The Magnificent 7 now looks more like the Magnificent 6 as Tesla falls from the crowd," billionaire investor Leon Cooperman , CEO of the Omega Family Office, said on CNBC's " Squawk Box " Tuesday. Meanwhile, there are now 29 companies that contributed more to S & P 500 earnings than Tesla, according to Strategas Securities. The research firm identified three companies with both market cap weighting and earnings contributions (for the next 12 months) larger than Tesla — Berkshire Hathaway , Broadcom and Eli Lilly . "Berkshire spent last year fliting with the top seven, but Broadcom and Lilly have steadily gained share," Strategas said in a note.

Persons: Tesla, Elon, Leon Cooperman, Berkshire, Eli Lilly, Lilly, Strategas, Warren, Eli Lilly's, — CNBC's Michael Bloom Organizations: Elon Musk's, Omega, Strategas Securities, Berkshire Hathaway, Broadcom, Berkshire, JPMorgan Locations: Warren Buffett's Berkshire

☆ Wall Street gives 2 of our healthcare stocks well-deserved price target bumps
▼ + stars: | 2024-02-07 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +6 min

Wall Street liked what it saw from GE Healthcare and Eli Lilly in their earnings reports, leading to a round of well-deserved price target bumps for the Club stocks. GE Healthcare fell slightly Wednesday, holding on to most of Tuesday's almost 11.7% surge. The biggest price target boost for GE Healthcare came from Piper Sandler, going to $94 per share from $84 while reiterating its buy-equivalent rating. Goldman Sachs, which has a hold rating on Eli Lilly, bumped its price target to $650 a share from $600. The GE Healthcare scanner is called the Revolution CT. Martin Schutt | picture alliance | Getty Images

Persons: Eli Lilly, tirzepatide, Lilly, it's, Piper Sandler, —, Mizuho, Wells Fargo, Evercore, Eli Lilly's, Lilly's, Eli, Truist, Cantor Fitzgerald, Morgan Stanley, Goldman Sachs, Jim Cramer's, Jim Cramer, Jim, Martin Schutt Organizations: GE Healthcare, Club, GE, Mizuho Securities, Electric, BMO Capital Markets, Truist Securities, CNBC, Bank of America, Barclays, Getty Locations: Amgen, China, Eli Lilly's, Wells Fargo, Jena , Germany

☆ Wall Street says Big Tech needs to take a breather after huge run. Here's our take
▼ + stars: | 2024-02-06 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "This is a consolidation day," Jim Cramer said Tuesday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, We're, Jim, We're bullish, Jim Cramer's Organizations: CNBC, Big Tech, Citigroup, GE Healthcare

Eli Lilly rode soaring demand for diabetes and weight-loss treatments to a better-than-expected finish in 2023, and the drugmaker expects momentum to carry into the new year. Lilly said on Tuesday that revenue could climb as much as 22% this year, as star sellers like the diabetes drug Mounjaro and its new weight-loss counterpart, Zepbound, gain market share. Mounjaro sales jumped 65% to $2.21 billion in the fourth quarter compared with the third quarter. Doctors also prescribe that drug off-label for weight loss, which is one of the hottest areas of pharmaceutical sales. The share price for Indianapolis-based Eli Lilly and Co. has climbed over 400% since the start of the decade.

Persons: Eli Lilly, Lilly, Doctors, David Ricks, “, ”, FactSet, donanemab Organizations: Company, Revenue, Drug Administration, Indianapolis Locations: Mounjaro, North Carolina

☆ Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
▼ + stars: | 2024-02-06 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a mid-stage trial. The condition is characterized by excess fat build-up and inflammation in the liver and can lead to liver scarring, also known as fibrosis. The trial followed around 190 adults with MASH with severe stages of liver scarring, Eli Lilly executives said on an earnings call Tuesday. It was less clear how much the drug reduced liver scarring, which was the second aim of the trial. Eli Lilly is "equally encouraged" by tirzepatide's results in reducing liver scarring, the company's chief scientific officer Dan Skovronsky said on the call.

Persons: Eli Lilly’s, Eli Lilly, tirzepatide, Dan Skovronsky, David Risinger, Eli Lilly's Organizations: Leerink, Novo Nordisk Locations: New York City, U.S

☆ Stocks making the biggest moves premarket: Spotify, Eli Lilly, Palantir, UBS and more
▼ + stars: | 2024-02-06 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

The compan y posted adjusted earnings of $2.49 per share on revenue of $9.35 billion. Analysts anticipated $2.22 per share on revenue of $8.93 billion, according to LSEG. The company's revenue of $3.42 billion also beat analysts' forecasts of $3.40 billion. Chegg expects revenue between $173 million to $175 million, lighter than the $180.1 million consensus estimate, per StreetAccount. UPS -- Shares of the delivery company rose more than 1% after UBS upgraded the stock to buy from neutral.

Persons: Eli Lilly, Tesla, Li, amortization, Rambus, Macheel, Jesse Pound, Sarah Min, Michelle Fox Theobald Organizations: Spotify, LSEG, UBS —, JPMorgan, UBS, BP, Deutsche Bank, StreetAccount, UPS Locations: Swiss, StreetAccount .

☆ Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue
▼ + stars: | 2024-02-06 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes drug, Mounjaro. Zepbound, which won approval from U.S. regulators in early November, raked in $175.8 million in sales for the fourth quarter. Shares of Eli Lilly were up 5% in premarket trading Tuesday. With a market cap of roughly $673 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.Eli Lilly will hold an earnings call with investors at 10:00 a.m.

Persons: Eli Lilly, Eli Lilly's, Mounjaro Organizations: LSEG, FactSet Locations: San Diego , California, U.S

☆ We're raising our price target on Eli Lilly by $120 after its excellent quarter
▼ + stars: | 2024-02-06 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +10 min

Bottom line Eli Lilly delivered a strong report Tuesday. Still, it's not a surprise to see shares of Eli Lilly fall nearly 2% Tuesday, to around $694 each. Despite doubling manufacturing capacity year over year in 2023, Eli Lilly said demand for its GLP-1s is "likely to outpace supply" this year. We're raising our Eli Lilly price target to $750 a share from $630, while reiterating our 2 rating on the stock, meaning we'd wait for a pullback before adding to our position. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly's, Lilly's, Eli Lilly, Mounjaro, Zepbound, it's, —, Jim Cramer, Anat Ashkenazi, NASH, Lilly, Jim, Jardiance, Verzenio, Trulicity, donanemab, Ashkenazi, Jim Cramer's, George Frey Organizations: Revenue, LSEG, U.S, Novo Nordisk, Food and Drug Administration, Analysts, Investors, FDA, CNBC, Bloomberg, Getty Locations: Mounjaro's, U.S, Mounjaro, Trulicity, Provo , Utah

☆ BofA's Geoff Meacham on Eli Lilly on Q4 results: The story has changed to diabetes and obesity
▼ + stars: | 2024-02-06 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBofA's Geoff Meacham on Eli Lilly on Q4 results: The story has changed to diabetes and obesityGeoff Meacham, Bank of America Securities senior pharmaceuticals analyst, joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes treatment, Mounjaro.

Persons: Geoff Meacham, Eli Lilly Organizations: Bank of America Securities

Still, Eli Lilly and Novo Nordisk appear to be making some encouraging progress. Eli Lilly wasn't the only weight loss drug producer to see positive supply developments in the last week. Novo Holdings, which owns almost 77% of the voting shares in Novo Nordisk, said Monday it will acquire drug manufacturer Catalent in a $16.5 billion deal. Novo Nordisk will then buy three of Catalent's manufacturing plants from Novo Holdings for $11 billion. Tema in November launched an ETF whose key holdings include companies benefiting from the hype around weight loss drugs.

Persons: Eli Lilly, Anat Ashkenazi, Incretin, Eli Lilly's, Ashkenazi, Eli Lilly wasn't, Yuri Khodjamirian, Danish drugmaker Organizations: Novo Nordisk, Holdings, Wegovy, Novo Holdings, CNBC, Tema, Nordisk, Reuters Locations: North Carolina, Novo, Tema, Brussels, Danish, U.S

☆ Tirzepatide: Weight loss drug helps significantly lower blood pressure in adults who are overweight or obese, study finds
▼ + stars: | 2024-02-05 | by ( Mira Cheng | ) edition.cnn.com time to read: +6 min

The participants had their blood pressure monitored for a day before beginning treatment and again after nine months of weekly tirzepatide injections. The results showed a significant decrease in the participants’ systolic blood pressure, the top number in blood pressure readings, which is a strong predictor of heart disease. It works similarly to semaglutide, the active compound in the weight loss drug Wegovy and its sister diabetes drug, Ozempic. Although there are effective blood pressure medications available, only about a quarter of people with hypertension have adequately controlled blood pressure, Hall said. He views the weight loss effect of the drug as a pleasant side effect that will make people more likely to take their medication.

Persons: —, Eli Lilly, ”, Harlan Krumholz, Michael E, Wegovy, it’s, Ania Jastreboff, Hall, Krumholz, tirzepatide, Dr, Sanjay Gupta, CNN’s Meg Tirrell Organizations: CNN, American Heart Association, Food and Drug Administration, Yale University, Department of Medicine, University of Mississippi Medical Center, Yale Obesity Research Center, CNN Health Locations: United States

☆ Here are Jim Cramer's rapid-fire takes on 5 stocks in the news Monday
▼ + stars: | 2024-02-05 | by ( Paulina Likos | ) www.cnbc.com time to read: +1 min

Jim Cramer said this deal is Novo's way to "get more product" and addresses the "tremendous shortage" of these high-demand drugs. Shares of Eli Lilly , a stock in the CNBC Investing Club 's portfolio, were also up more than 4% ahead of Tuesday's earnings. Snap – The social media firm laid off 10% of its workforce ahead of Tuesday's earnings. Jim pointed out that Club name Starbucks (SBUX) has also been experiencing the same thing. Jim said buy McDonald's stock on weakness.

Persons: Jim Cramer, Eli Lilly, Lilly, Cramer, Cigna –, Cantor Fitzgerald, Jim Organizations: Nordisk, Catalent, CNBC, Microsoft, RBC Capital, Humana, Starbucks, Mattel –, JPMorgan, Vision, Apple Locations: Danish, Israel

Search resuls for: "Mounjaro"

25 mentions found